Summary
Beta-carotene is a plant carotenoid that mainly serves as a provitamin A source. It appears in foods such as carrots, sweet potatoes, and leafy greens, and it is also sold in standalone supplements, multivitamins, and older eye-health formulas.
Although beta-carotene has antioxidant activity, routine supplementation has not shown meaningful benefit for preventing cancer, cardiovascular disease, age-related macular degeneration onset, cataract, or death in generally well-nourished adults. The most important clinical warning is increased lung-cancer risk in smokers, former smokers, and asbestos-exposed groups. The original AREDS eye formula once included beta-carotene, but beta-carotene-free AREDS2 is now generally preferred.
Quick Facts
What is it useful for?
It is mainly useful as a provitamin A source when intake is inadequate, not as a routine cancer, heart, or longevity supplement.
Supplement types
Products include standalone beta-carotene, mixed carotenoids, and multivitamins that combine beta-carotene with retinyl esters.
Interactions
Combining it with vitamin A or oral retinoid products can raise total vitamin A exposure. Orlistat can reduce absorption.
Side effects
Yellow-orange skin discoloration is the best-known effect. Supplemental use is more concerning in smokers, former smokers, and asbestos-exposed people because lung-cancer risk increases in trials.
Other possible benefits
It was part of the original AREDS formula for intermediate AMD, but beta-carotene-free AREDS2 is now preferred.
Regulatory status
It is sold in the US and Europe, but routine prevention claims are not supported and current EU guidance says smokers should avoid it.
What We Already Know About It
Its core biology is well established. Beta-carotene is a carotenoid made by plants and some microorganisms, and in humans it functions mainly as a provitamin A source. The body can convert it into retinol activity equivalents when needed, but that conversion is not fixed. Supplemental beta-carotene is generally more efficiently used than beta-carotene trapped within intact foods, and the amount converted depends on the food matrix, fat intake, nutritional status, and likely genetics. This is why food and supplement doses are not nutritionally equivalent on a simple milligram-for-milligram basis. NIH ODS — Vitamin A and Carotenoids Fact Sheet; Bioconversion of dietary provitamin A carotenoids to vitamin A in humans.
The clinical outcome profile is also fairly clear. Beta-carotene supplements do not have good evidence for preventing cancer, cardiovascular disease, AMD onset, cataract, or all-cause mortality in generally well-nourished adults. The strongest evidence of harm is in current smokers, former smokers, and asbestos-exposed groups, where large randomized trials found increased lung-cancer incidence and, in some analyses, higher mortality. The one historically important exception was the original AREDS formula for intermediate AMD, but later AREDS2 replaced beta-carotene with lutein and zeaxanthin while retaining similar or better benefit. USPSTF — Vitamin Supplementation to Prevent CVD and Cancer; PubMed — ATBC trial; PubMed — CARET trial; National Eye Institute — AREDS/AREDS2 FAQ.
Summary of Relevant Scientific Research
NIH Office of Dietary Supplements — Conversion and Product Differences
The NIH fact sheet explains that beta-carotene is a provitamin A carotenoid and that supplemental and dietary forms are not equivalent: 1 mcg RAE equals 2 mcg supplemental beta-carotene but 12 mcg dietary beta-carotene from food. It also notes product labels may contain beta-carotene, retinyl esters, or both. NIH ODS — Vitamin A and Carotenoids Fact Sheet.
USPSTF — No Routine Prevention Benefit
The U.S. Preventive Services Task Force and its evidence review concluded that beta-carotene should not be used for prevention of cardiovascular disease or cancer in community-dwelling, nonpregnant adults because benefits were absent and harms were identified in some groups. USPSTF Recommendation; PubMed — Supporting evidence review.
ATBC Study — Harm in Male Smokers
In 29,133 male smokers, 20 mg of beta-carotene daily for 5 to 8 years increased lung-cancer incidence by about 18% and overall mortality by about 8%, directly challenging the idea that antioxidant supplementation is automatically protective. PubMed — ATBC trial results.
CARET — More Lung Cancers and Deaths
CARET tested 30 mg beta-carotene plus 25,000 IU retinyl palmitate in current or former smokers and asbestos-exposed workers. The trial was stopped early because the active-treatment group had more lung cancers and more deaths. PubMed — CARET trial.
National Eye Institute and Cochrane — AREDS Context and AREDS2 Replacement
The original AREDS formula reduced progression to advanced AMD in a defined high-risk group, but AREDS2 showed that replacing beta-carotene with lutein and zeaxanthin produced similar or better outcomes while avoiding the smoking-related lung-cancer concern. Antioxidant supplements did not prevent AMD onset in healthy adults. National Eye Institute — About AREDS and AREDS2; Cochrane — AMD progression review; Cochrane — AMD prevention review.
Beliefs, Myths & Unproven Claims
More antioxidant must be better
This common idea is not supported by randomized trial evidence. Antioxidant biology is context dependent, and high-dose isolated beta-carotene supplements did not reproduce the benefits associated with eating carotenoid-rich foods; in some high-risk groups, outcomes became worse rather than better. USPSTF Recommendation; PubMed — 2022 mortality meta-analysis; PubMed — Cardiovascular review.
It is a general eye-health supplement for everyone
The evidence is narrower than marketing suggests. Antioxidant supplements do not prevent AMD from developing in healthy adults, and the original AREDS benefit came from a combination formula used in people with intermediate AMD or advanced AMD in one eye, not from beta-carotene alone. Cochrane — AMD prevention review; Cochrane — AMD progression review; National Eye Institute — AREDS/AREDS2 FAQ.
Food studies prove the supplement works
Higher dietary or blood beta-carotene is often linked with better outcomes in observational research, but that does not prove capsule benefits. Those patterns are more plausibly explained by healthier diets and lifestyles than by isolated supplement effects. PubMed — Observational review on dietary beta-carotene and mortality; PubMed — 2023 cancer meta-analysis.
Detailed Research Observations
Food and supplement forms are not nutritionally equivalent
Beta-carotene is not just an antioxidant label on a bottle; it is a specific carotenoid that humans use mainly as a provitamin A compound. That role is real, but the way the body handles beta-carotene depends heavily on how it is delivered. The NIH fact sheet notes that 1 mcg RAE equals 2 mcg supplemental beta-carotene but 12 mcg dietary beta-carotene from food, showing that food and supplement amounts are not interchangeable on a simple milligram basis. Human bioconversion work also shows that release from the food matrix, fat intake, vitamin A status, and likely genetics all influence how much vitamin A is actually produced. Oil-based supplemental forms may be more bioavailable than carotenoids locked inside plant tissues, but higher absorption does not automatically translate into better long-term health outcomes. NIH ODS — Vitamin A and Carotenoids Fact Sheet; Bioconversion of dietary provitamin A carotenoids to vitamin A in humans.
Cancer and cardiovascular prevention claims did not hold up in trials
Beta-carotene was heavily promoted after observational studies linked carotenoid-rich diets with lower disease risk, but randomized testing did not confirm that isolated supplementation prevents major chronic disease. In lower-risk populations such as the Physicians' Health Study and the Women's Health Study, beta-carotene did not significantly reduce total cancer or major site-specific cancers, and it did not provide clear cardiovascular or mortality benefit. More recent meta-analyses reinforce that pattern: no overall mortality benefit, no convincing cardiovascular protection, and no basis for recommending beta-carotene for cancer prevention. This gap between favorable food-pattern associations and disappointing supplement trials is one of the clearest examples of why a nutrient within a healthy diet should not automatically be assumed to work the same way as a pill. PubMed — Physicians' Health Study; PubMed — Women's Health Study; PubMed — 2022 mortality meta-analysis; PubMed — 2023 cancer meta-analysis; PubMed — Cardiovascular review.
The smoker and asbestos harm signal changed the safety picture
The decisive safety issue is not a minor side effect but a strong randomized-trial harm signal in specific high-risk groups. In ATBC, male smokers taking 20 mg per day had higher lung-cancer incidence and higher overall mortality. In CARET, current or former smokers and asbestos-exposed workers given 30 mg beta-carotene plus retinyl palmitate had more lung cancers and more deaths, leading the trial to stop early. Later reviews and guidance kept that conclusion in place rather than weakening it. For smokers, former smokers, and people with asbestos exposure, avoiding beta-carotene supplements is therefore a risk-based recommendation supported by clinical evidence rather than a theoretical precaution. PubMed — ATBC trial; PubMed — CARET trial; USPSTF Recommendation; PubMed — 2022 mortality meta-analysis.
Eye-health evidence is real but much narrower than advertising suggests
The original AREDS formula did reduce progression to advanced AMD by about 25% in people with intermediate AMD or advanced AMD in one eye, but that finding applies to a multi-nutrient combination in a defined disease stage, not to beta-carotene as a general eye-health supplement. AREDS2 then showed that removing beta-carotene and using lutein plus zeaxanthin maintained similar or better outcomes while avoiding the lung-cancer concern for people with smoking history. Cochrane reviews also separate treatment from prevention: antioxidant supplements may help slow progression in established intermediate AMD within AREDS-type formulas, but they do not prevent AMD from developing in healthy adults, and the AREDS formulations did not affect cataract. National Eye Institute — About AREDS and AREDS2; National Eye Institute — AREDS/AREDS2 FAQ; Cochrane — AMD progression review; Cochrane — AMD prevention review.
Food-based patterns look better than pills, and product labels matter
Prospective observational studies often find lower mortality among people with higher dietary beta-carotene intake or higher blood beta-carotene levels, but that does not prove that isolated supplements improve survival. People who eat more carotenoid-rich foods usually differ in many other ways, including overall diet quality and lifestyle. At the product level, labels also matter: some supplements provide beta-carotene alone, some combine it with preformed vitamin A, and older eye formulas differ from modern AREDS2 products. That affects both nutrient accounting and safety, especially when beta-carotene is paired with retinyl esters or used by people with smoking history. The practical implication is that colorful plant foods remain the more defensible default, while product choice and personal risk factors matter if supplements are considered. PubMed — Observational review on dietary beta-carotene and mortality; NIH ODS — Vitamin A and Carotenoids Fact Sheet; National Eye Institute — AREDS/AREDS2 FAQ.
Regulatory Status (EU and US)
United States
Beta-carotene is widely sold as a dietary supplement in the United States, but the main preventive-care recommendation is negative rather than supportive. The USPSTF recommends against beta-carotene supplements for prevention of cardiovascular disease or cancer in community-dwelling, nonpregnant adults because evidence shows no net benefit and points to harm in some groups. The NIH Office of Dietary Supplements similarly frames beta-carotene mainly as a provitamin A source and notes that the Food and Nutrition Board does not advise routine use in the general population except to prevent deficiency. USPSTF Recommendation; NIH ODS — Vitamin A and Carotenoids Fact Sheet.
European Union
European guidance has become more cautious over time. EFSA's 2012 statement found that exposures below 15 mg per day did not raise concern in the general population, including heavy smokers, but EFSA's 2024 opinion is stricter and states that smokers should avoid food supplements containing beta-carotene and that general-population use should be limited to meeting vitamin A requirements. For eye-health products, National Eye Institute guidance also has practical relevance: current and former smokers are directed toward AREDS2 instead of older beta-carotene-containing AREDS formulas. EFSA — 2012 beta-carotene statement; EFSA — 2024 beta-carotene opinion; National Eye Institute — AREDS/AREDS2 FAQ.
Dosage and Standardization
No routine preventive dose is supported. For vitamin A conversion, 1 mcg RAE equals 2 mcg supplemental beta-carotene; doses tied to concern in trials were 15–30 mg/day, and smokers should avoid supplements.
Safety And Interactions
The best-established non-serious adverse effect of long-term excess beta-carotene is carotenodermia, a yellow-orange discoloration of the skin that is generally reversible. Food sources are considered safe, and beta-carotene is not known to share the teratogenic risk associated with excessive preformed vitamin A. However, this relatively benign profile does not apply equally to all populations: in current smokers, former smokers, and people with asbestos exposure, randomized trials and later reviews show increased lung-cancer risk, and some analyses also show increased mortality. NIH ODS — Vitamin A and Carotenoids Fact Sheet; PubMed — ATBC trial; PubMed — CARET trial; PubMed — 2022 mortality meta-analysis.
Orlistat can reduce absorption of fat-soluble compounds, including carotenoids, so supplemental beta-carotene may be less effectively absorbed. People taking oral retinoids or multiple vitamin A-containing products should review labels carefully because combined exposure may become excessive, especially when beta-carotene is paired with retinyl esters. Mayo Clinic also lists yellow-orange skin change as the common visible side effect and notes rarer effects such as diarrhea, dizziness, joint pain, and unusual bleeding or bruising. Older adults with any smoking history should choose AREDS2 rather than older beta-carotene-containing AREDS products. NIH ODS — Vitamin A and Carotenoids Fact Sheet; Mayo Clinic — Beta-carotene oral route; National Eye Institute — AREDS/AREDS2 FAQ.
Conclusion
Beta-carotene is a real nutrient with a real biochemical role, but that does not make it a good routine supplement. The strongest evidence supports its identity as a provitamin A carotenoid and confirms that food and supplemental forms behave differently in the body. Beyond that, the clinical evidence is mostly disappointing or negative for common supplement claims.
In generally well-nourished adults, beta-carotene supplements do not convincingly prevent cancer, cardiovascular disease, AMD onset, cataract, or death. The most important exception in the literature was the original AREDS formula for intermediate AMD, but that historical use has largely been superseded by beta-carotene-free AREDS2 because similar or better benefit can be achieved with less lung-cancer risk. For most adults, the practical takeaway is to prioritize carotenoid-rich foods and reserve supplementation for clearly defined nutritional or clinical reasons rather than routine prevention.
Disclaimer
Disclaimer: We attempt to do our best to find relevant, accurate and most up to date information available in both, the public domain and in the clinical and medical research community. We recommend reviewing scientific sources for official information on the subject. This post is not intended as medical advice. Each individual person's health conditions vary and we advise to consult a doctor before taking any supplements.